A widely shared headline claims that a diabetes medicine is linked to a 33% higher risk of heart attack and heart failure. The drug in question is rosiglitazone, a type 2 diabetes medicine sold under the brand name Avandia.
The underlying research is real, but the headline needs important context. The analysis was published in 2020 and examined data from more than 130 clinical trials involving over 48,000 adults. It was not a new 2026 study.
What Was the Drug?
Rosiglitazone belongs to a class of diabetes medicines called thiazolidinediones (TZDs).
These medications improve the body’s sensitivity to insulin, helping lower blood glucose in people with type 2 diabetes.
However, rosiglitazone has long been associated with concerns about cardiovascular effects, particularly fluid retention and heart failure.
What Did the Large Analysis Find?
Researchers analyzed more than 130 randomized clinical trials comparing rosiglitazone with a control treatment for at least 24 weeks.
The analysis included more than 48,000 participants, making it substantially larger than many earlier analyses of the drug’s cardiovascular safety.
The researchers found evidence suggesting an increased risk of certain cardiovascular outcomes associated with rosiglitazone.
Importantly, the exact risk estimates depend on which dataset and statistical analysis are considered. Therefore, saying simply that the drug “causes a 33% higher risk” can be misleading.
What About Heart Failure?
Heart failure is one of the most important concerns with rosiglitazone.
The medication can cause fluid retention, which can worsen or trigger heart failure in susceptible people.
Warning symptoms can include:
- Shortness of breath
- Swelling of the ankles or legs
- Rapid weight gain from fluid
- Unusual tiredness
- Difficulty breathing when lying down
Anyone taking a medication associated with heart-failure risk who develops these symptoms should contact their healthcare professional promptly.
What About Heart Attacks?
The relationship between rosiglitazone and heart attack has been debated for years.
Some analyses have suggested an increased risk, while others have produced less definitive findings. The large 2020 analysis was intended to clarify uncertainty by incorporating individual-patient data from many trials.
That is why a responsible headline should avoid presenting a single percentage as an absolute certainty for every patient.
Should You Stop Taking It?
No—don’t stop a prescribed diabetes medicine because of a headline.
If you’re taking rosiglitazone, speak with your doctor about whether it remains appropriate for you.
Your doctor may consider factors such as:
- Your blood glucose control
- Cardiovascular history
- History of heart failure
- Kidney function
- Other medications
- Other available diabetes treatments
- Your individual risks and benefits
Modern diabetes treatment includes several medication classes with demonstrated cardiovascular benefits in appropriate patients. For example, current cardiovascular guidelines recognize cardiovascular benefits from certain SGLT2 inhibitors and GLP-1 receptor agonists in people with type 2 diabetes and established cardiovascular disease.
Why Medication Headlines Can Be Misleading
A percentage such as “33% higher risk” describes a relative increase, not necessarily a 33-percentage-point increase in someone’s personal chance of having a heart attack.
For example, if a hypothetical risk increased from 1% to 1.33%, that would be a 33% relative increase but an absolute increase of only 0.33 percentage points.
The actual absolute risk depends on the individual and the population being studied.
The Bottom Line
The 48,000-patient analysis provides important evidence concerning the cardiovascular safety of rosiglitazone, particularly the established concern surrounding heart failure.
But the viral claim that a “new study” has suddenly discovered that the drug causes a 33% increase in heart attack and heart failure is overstated. The major analysis dates to 2020, and cardiovascular risk needs to be interpreted in the context of the patient’s overall health and treatment options.
If you take rosiglitazone, don’t discontinue it on your own. Discuss the risks and alternatives with your healthcare professional.